Proteopedia:Featured SEL/1
From Proteopedia
(Difference between revisions)
(image must be a link) |
|||
(3 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
<table> | <table> | ||
- | <tr><td>[[Image:Anim Avian Influenza Neuraminidase.gif]]</td></tr> | ||
- | <tr><td>'''Avian Influenza Neuraminidase'''</td></tr> | ||
- | <tr><td>''Eric Martz''</td></tr> | ||
<tr><td> | <tr><td> | ||
- | <div class= | + | <imagemap> |
- | + | Image:Anim Avian Influenza Neuraminidase.gif | |
+ | default [[Avian_Influenza_Neuraminidase,_Tamiflu_and_Relenza]] | ||
+ | </imagemap> | ||
+ | </td></tr> | ||
+ | <tr><td><div class='scrolling'>'''Avian Influenza Neuraminidase'''<br> | ||
+ | ''Eric Martz''<br> | ||
+ | The first new influenza virus to emerge as an imminent pandemic threat in the 21st century is H1N1 swine flu. The drug '''oseltamivir''' (Tamiflu®) inhibits flu neuraminidase, a component necessary for virus spread, in susceptible flu strains. The development of oseltamivir was guided, in part, by crystallographically determined structures of flu neuraminidase, which is a homotetramer, shown with oseltamivir bound. Oseltamivir was designed to fit N2/N9 (neuraminidases from other strains of flu). Serendipitously, it also fits N1 by induced fit. | ||
+ | |||
+ | >>> [[Avian_Influenza_Neuraminidase%2C_Tamiflu_and_Relenza|Visit this page]] >>> | ||
</div> | </div> | ||
</td></tr> | </td></tr> | ||
</table> | </table> | ||
+ | |||
+ | [[Category:Featured in Selected Pages]] |
Current revision
Avian Influenza Neuraminidase
Eric Martz >>> Visit this page >>> |